ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2256

Analysis of the Factors That Contribute to the Differences Between DAS28-ESR and DAS28-CRP

Toshihiro Matsui1, Hirotaka Tsuno2, Jinju Nishino3, Yoshiaki Kuga4, Atsushi Hashimoto5 and Shigeto Tohma6, 1Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, 2Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, 3Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, 4Wakaba Hospital, Saitama, Japan, 5Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, 6Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: body mass, Disease Activity, remission and sex bias

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: It is widely accepted that the remission rate of DAS28-CRP is larger than that of DAS28-ESR, SDAI, and CDAI in patients with rheumatoid arthritis. DAS28-CRP was introduced to be comparable to DAS28-ESR and the same cut-off values of disease activity category were generally used for both DAS28. However, it had been reported that DAS28-CRP underestimates the disease activity compared with DAS28-ESR (Matsui T, et al. Ann Rheum Dis 2007;66:1221) and that the differences between DAS28-ESR and DAS28-CRP (DAS28DIF) were affected by gender and disease duration (Castrejon I, et al. Clin Exp Rheumatol 2008;26:769). It is very important to know the factors which affect DAS28DIF for evaluating the data by DAS28-CRP.The purpose of this study is to analyze the factors which have an influence on DAS28DIF.

Methods: We analyzed the data from 5987 patients with rheumatoid arthritis (RA) registered in NinJa (National Database of Rheumatic Diseases by iR-net in Japan) 2011. The mean age was 63.1±12.9 years old, disease duration was 12.1±10.8 years, and 80.7% of the patients were female. The mean DAS28-ESR and DAS28-CRP was 3.24±1.28 and 2.58±1.10, respectively (mean DAS28DIF=0.659). Multivariate linear regression analyses were conducted. Variables that were significant at p<0.01 on the univariate analysis were entered into the multivariate model.

Results: A univatiate analysis showed that several variables (gender, age, disease duration, stage, class, mHAQ, ESR, CRP, PtPainVAS, PtGVAS, DrVAS, artificial joint, TJC28, SJC28) were associated with DAS28DIF with p<0.01. A multivariate linear regression analysis demonstrated that ESR (standard partial regression coefficient :0.633),  female gender (0.194), age (0.119), mHAQ (-0.087), and BMI (-0.037) were associated with DAS28DIF (coefficient of determination:0.474). Category analysis also revealed that value of DAS28DIF was significantly higher with increasing ESR, age, disease duration, class, mHAQ, DAS28-ESR, DAS28-CRP, and with decreasing BMI (Jonckheere-Tepstra trend test, p<0.001). There was significant difference in DAS28DIF between male (0.41) and female (0.72) (Wilcoxon signed-rank test, p<0.001). Mean DAS28DIF was -0.002 in patients whose ESR was 11 mm/hr or less. Cut-off value for DAS28-CRP calculated by regression analysis between DAS28-ESR and DAS28-CRP was 2.1 for remission, 2.5 for low disease activity and 4.0 for high disease activity, respectively.

Conclusion: This study showed that DAS28DIF can be affected by many kinds of valuables. We should pay attention to the background of the patients when analyzing the data by using DAS28-CRP and evaluating the cut-off value of remission for DAS28-CRP based on that of DAS28-ESR.


Disclosure:

T. Matsui,
None;

H. Tsuno,
None;

J. Nishino,
None;

Y. Kuga,
None;

A. Hashimoto,
None;

S. Tohma,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-the-factors-that-contribute-to-the-differences-between-das28-esr-and-das28-crp/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology